Related references
Note: Only part of the references are listed.Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?
Seung Tae Kim et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer
Chanida Vinayanuwattikun et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer
Anneli Dowler Nygaard et al.
LUNG CANCER (2013)
Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis
Paola Ulivi et al.
PLOS ONE (2013)
Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
Xiao Zhao et al.
RESPIRATION (2013)
Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?
Shiyang Pan et al.
BIOMEDICINE & PHARMACOTHERAPY (2012)
Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing
Azeet Narayan et al.
CANCER RESEARCH (2012)
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Elizabeth A. Punnoose et al.
CLINICAL CANCER RESEARCH (2012)
Detection of EGFR Somatic Mutations in Non-Small Cell Lung Cancer (NSCLC) Using a Novel Mutant-Enriched Liquidchip (MEL) Technology
Li Zhang et al.
CURRENT DRUG METABOLISM (2012)
Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer
Raffaele Califano et al.
DRUGS (2012)
Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC
Adam Szpechcinski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA
Tomomi Nakamura et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Koichi Goto et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer
Su Man Lee et al.
MOLECULES AND CELLS (2012)
Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients
Raquel Catarino et al.
PLOS ONE (2012)
A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry
Barbara Angulo et al.
PLOS ONE (2012)
A new approach for detecting low-level mutations in next-generation sequence data
Mingkun Li et al.
GENOME BIOLOGY (2012)
Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer
Youwei Zhang et al.
CANCER LETTERS (2011)
Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy
Young Joo Lee et al.
CLINICAL CANCER RESEARCH (2011)
RARβ2 gene methylation level in the circulating DNA from blood of patients with lung cancer
Anastasia A. Ponomaryova et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2011)
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-enriched Sequencing in Chinese Patients with Advanced Non-small Cell Lung Cancer
B. Jiang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2011)
Epithelial-Specific Methylation Marker A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer
Chanida Vinayanuwattikun et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer
Rafael Sirera et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer
Carina Roth et al.
MOLECULAR ONCOLOGY (2011)
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
Marie Brevet et al.
LUNG CANCER (2011)
The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients
Carlos Camps et al.
LUNG CANCER (2011)
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
Fernanda Salazar et al.
LUNG CANCER (2011)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer
Shuhang Wang et al.
CLINICAL CANCER RESEARCH (2010)
Frequent Epigenetic Inactivation of Deleted in Lung and Esophageal Cancer 1 Gene by Promoter Methylation in Non-Small-Cell Lung Cancer
Youwei Zhang et al.
CLINICAL LUNG CANCER (2010)
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
S. Kumar et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer
Guo Jian et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Kenichi Suda et al.
Journal of Thoracic Oncology (2010)
A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients
Der-An Tsao et al.
LUNG CANCER (2010)
Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection
Mohit Agarwal et al.
LUNG CANCER (2010)
Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer
Y. W. Zhang et al.
NEOPLASMA (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer
Youwei Zhang et al.
CANCER SCIENCE (2009)
Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients
Tony K. F. Yung et al.
CLINICAL CANCER RESEARCH (2009)
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
Yanan Kuang et al.
CLINICAL CANCER RESEARCH (2009)
Detection of' epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-celi lung cancer
Chen He et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome
Andreas-Claudius Hoffmann et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comparison of Circulating Plasma DNA Levels between Lung Cancer Patients and Healthy Controls
Kyong-Ah Yoon et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Lack of Prognostic Significance of Serum DNA Methylation of DAPK, MGMT, and GSTPI in Patients With Non-Small Cell Lung Cancer
A. C. Hoffmann et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer
Philip C. Mack et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer
Massimiliano Paci et al.
LUNG CANCER (2009)
REAL-TIME PCR QUANTIFICATION OF PLASMA DNA IN NON-SMALL CELL LUNG CANCER PATIENTS AND HEALTHY CONTROLS
A. Szpechcinski et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2009)
3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer
Giovanna E. Carpagnano et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients - A study of the Perugia multidisciplinary team for thoracic oncology
Vienna Ludovini et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer
Rafael Sirera et al.
LUNG CANCER (2008)
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
Pasi A. Jaenne
LUNG CANCER (2008)
Cell-free DNA resuscitated for tumor testing
Michael Fleischhacker et al.
NATURE MEDICINE (2008)
The origin of circulating free DNA
Maniesh van der Vaart et al.
CLINICAL CHEMISTRY (2007)
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
H. Kimura et al.
BRITISH JOURNAL OF CANCER (2007)
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine
Juergen R. Fischer et al.
LUNG CANCER (2007)
Autoimmunity versus tolerance: Can dying cells tip the balance?
Irene C. B. Viorritto et al.
CLINICAL IMMUNOLOGY (2007)
Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer
Victor Cohen et al.
CANCER (2006)
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
Michio Inukai et al.
CANCER RESEARCH (2006)
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer
Hideharu Kimura et al.
CLINICAL CANCER RESEARCH (2006)
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer
Hideharu Kimura et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
M Esteller
ONCOGENE (2002)
Microsatellites in different eukaryotic genomes:: Survey and analysis
G Tóth et al.
GENOME RESEARCH (2000)
Share Paper
